Abstract

G.N. Gildeeva, A.V. Belostotsky, O.V. Gridnev, V.I. Yurkov

Since the middle of the last century, there has been an increase in the prevalence rate of allergic diseases, which also continues in recent years. The projected further growth of the allergic diseases frequency requires the development of new approaches in order to find solution for this problem, in particular the use of new modern medicines. The article presents the pharmaceutical characteristics and results of an open-label randomized clinical trial in relation to the effectiveness and safety (phase III) of a new anti-allergic medical product, Theoritin, in comparison with the reference preparation Aerius (desloratadine). This clinical trial involved 164 patients with chronic spontaneous urticaria (CSU). The research results indicate the noninferiority and comparable safety of the medical product Theoritin in relation to changes (decrease) in the severity of CSU symptoms after 14 days of therapy.